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Background: Lymphangioleiomyomatosis is a rare disease occurring almost exclusively in women. Diagnosis often
requires surgical biopsy and the clinical course varies between patients with no predictors of progression. We
evaluated recent diagnostic guidelines, clinical features and serum biomarkers as diagnostic and prognostic tools.
Methods: Serum vascular endothelial growth factor-D (VEGF-D), angiotensin converting enzyme (ACE), matrix
metalloproteinases (MMP) -2 and -9, clinical phenotype, thoracic and abdominal computerised tomography, lung
function and quality of life were examined in a cohort of 58 patients. 32 healthy female controls had serum
biomarkers measured.
Results: Serum VEGF-D, ACE and total MMP-2 levels were elevated in patients. VEGF-D was the strongest
discriminator between patients and controls (median = 1174 vs. 332 pg/ml p< 0.0001 with an area under the
receiver operating characteristic curve of 0.967, 95% CI 0.93-1.01). Application of European Respiratory Society
criteria allowed a definite diagnosis without biopsy in 69%. Adding VEGF-D measurement to ERS criteria further
reduced the need for biopsy by 10%. VEGF-D was associated with lymphatic involvement (p = 0.017) but not the
presence of angiomyolipomas.
Conclusions: Combining ERS criteria and serum VEGF-D reduces the need for lung biopsy in LAM. VEGF-D was
associated with lymphatic disease but not lung function.
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Lymphangioleiomyomatosis (LAM) is a rare lung disease
which almost exclusively affects women and generally pre-
sents before the menopause [1,2]. It can occur sporadically
or in association with the genetic condition tuberous scler-
osis complex (TSC): both sporadic and TSC-LAM are asso-
ciated with mutations in the TSC genes[3]. Histologically,
LAM is characterised by the abnormal growth of atypical,
smooth muscle-like LAM cells in the lungs leading to lung
cysts, airway obstruction and in many cases, respiratory fail-
ure. Obstruction of axial lymphatics by LAM cells can
cause lymphadenopathy and chylous collections[4]. In* Correspondence: simon.johnson@nottingham.ac.uk
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reproduction in any medium, provided the oraddition, around 60% of patients with sporadic LAM and
most patients with TSC-LAM have one or more angiomyo-
lipomas[5][6][7], benign tumours which share a common
ancestry with pulmonary LAM cells [3,8-10]. Importantly,
high resolution computerised tomography (HRCT) alone is
not diagnostic of LAM and patients undergoing transplant
for ‘LAM’ have been found to have other diseases after
examination of the explanted lungs [11,12]. Lung biopsy is
often used to confirm diagnosis, but recent clinical guide-
lines specify that a definitive diagnosis can be made without
lung biopsy in the presence of lung cysts, plus evidence of
either angiomyolipomas, chylous collections or TSC
(Table 1) [13]. These diagnostic criteria, based on expert
opinion, have not yet been formally evaluated. With the ad-
vent of disease specific treatments such as sirolimus [14,15]
it is increasingly important to make the correct diagnosis.
Furthermore, LAM is a variable disease with some patientsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of the ERS guidelines for the diagnosis
of LAM
Definite LAM 1. Characteristic or compatible lung HRCT AND
lung biopsy fitting the pathological criteria for LAM OR
2. Characteristic lung HRCT and any of the following:
• Angiomyolipoma (kidney)
• Thoracic or abdominal chylous effusion
• Lymphangioleiomyoma or lymph node involvement by LAM
• Definite or probable TSC
Probable LAM 1. Characteristic HRCT and compatible clinical history OR
2. Compatible HRCT and any of the following:
• Angiomyolipoma (kidney)
• Thoracic or abdominal chylous effusion
Possible LAM Characteristic or compatible HRCT
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for many years. It is currently not possible to predict with
confidence the likely clinical course at presentation which
is unsettling for patients and makes planning treatment dif-
ficult [16].
Circulating biomarkers offer a potential non-invasive
method for aiding diagnosis, monitoring disease progres-
sion and predicting prognosis. Several putative biomarkers
have already been identified in LAM. Vascular endothelial
growth factor-D (VEGF-D), a ligand for the lymphatic
growth-factor receptor VEGFR-3/Flt-4, is elevated in
serum of patients with LAM compared with healthy volun-
teers and patients with other cystic lung diseases. The clin-
ical utility of VEGF-D is not clear at present, however it
has been suggested that a serum VEGF-D level of
>800 pg/ml in combination with typical cystic changes on
HRCT is specific for LAM [17] though a VEGF-D level
<800 pg/ml does not exclude the diagnosis [18]. Matrix
metalloproteinases (MMPs) are a family of enzymes
involved in many processes including extracellular
matrix remodelling, angiogenesis, migration and cell
signalling [19,20]. Imbalance between MMPs and their
inhibitors has been implicated in a variety of pulmon-
ary disorders including LAM and elevated MMP-9,
has been observed in the serum of LAM patients [21].
Finally, membrane bound ACE and other elements of
the renin-angiotensin system have been identified in
LAM cells by immunohistochemistry [22] and we have
noted elevated serum angiotensin converting enzyme
(ACE) in patients with LAM.
In order to determine if these clinical guidelines and bio-
markers can improve clinical care for LAM patients by re-
ducing the need for invasive diagnostic investigations and
making more accurate predictions of prognosis, we have
compared the clinical utility of serum VEGF-D, MMP-2,
MMP-9 and ACE with the recent ERS diagnostic guide-
lines, health-related quality of life and clinical phenotype in
a national cohort of patients with LAM.Methods
Subjects
Patients were all receiving clinical care at the national re-
ferral centre for LAM in the UK. Patients were either par-
ticipating in a clinical trial where baseline data were
used, (NCT00989742, MHRA 03057/0032/001 -002,
EUDRACT 2007-003745-32, NRES 07/H0403/165) or
were in an observational cohort with Nottingham Ethics
Committee approval (NRES 05/Q2403/187). All patients
provided informed consent. Patients were classified as hav-
ing either definite or probable LAM according to ERS con-
sensus criteria (Table 1).
All were women over the age of 18. Spirometry and
transfer factor (TLCO) were measured according to
ARTP/BTS standards [23]. Retrospective lung function
results were obtained from clinical records. As short
term observation of lung function reduces the accuracy
of rate of decline estimates for FEV1 [16], serial data
were used only when greater than three years of obser-
vation were available. Thoracic and abdominal HRCT
were performed for the clinical trial or if indicated clin-
ically. All patients had blood drawn for biomarker ana-
lysis. Full blood count, differential white cell count and
C-reactive protein (CRP) were also measured to exclude
intercurrent infection but were not part of the bio-
marker analysis. Participants in the clinical trial com-
pleted St George’s Respiratory Questionnaires (SGRQ).
Thirty two healthy control women over the age of 18
with no prior history of lung disease had blood taken for
biomarker analysis (Nottingham University Ethics Com-
mittee approval BT A27 08 2009) with informed
consent.
Serum collection and storage
Blood was collected in serum separator tubes, allowed to
clot for 30 minutes at 4°C, centrifuged at 4000 G for 10
minutes and serum stored in aliquots at −80°C.
VEGF-D, MMP-2, MMP-9 and ACE assays
Serum VEGF-D and MMP-2 were measured using
Quantikine Human VEGF-D and MMP-2 Immunoassays
(R&D Systems, Minneapolis, MN). Serum MMP-9 was
measured using the Duoset Human MMP-9 Immuno-
assay (R&D Systems) with a previously validated serum
dilution of 1:1000 [24,25]. Serum ACE was determined
by colourimetric assay based on hydrolysis of furylacry-
loylphenylalanylglycylglycine to furylacryloylphenylala-
nine and glycylglycine by serum ACE using an Olympus
AU 2700 automated analyser (Olympus Diagnostics,
Watford, UK).
Interpretation of radiology
CT scans were examined independently by two consultant
radiologists (MK and KSP) blinded to other study data
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lymphatic involvement and renal angiomyolipomas. Only
a consensus between both radiologists was accepted. Cases
where agreement was not reached were omitted from this
part of the study.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.02 (GraphPad Software, San Diego, California, USA)
and SPSS 16 (SPSS Inc., Chicago, Illinois, USA). Com-
parison of age and biomarkers between groups was per-
formed using the Mann–Whitney test and correlation
between age and biomarkers was examined using Spear-
man’s rho (statistical significance set at p< 0.05 for a 2-
tailed test). Predictive ability of serum biomarkers was
assessed by receiver operator characteristic (ROC) curve
analysis.
Results
Characteristics of study subjects and application of ERS
criteria
Fifty eight patients were recruited. According to ERS
criteria, 45 had definite and 13 had probable LAM [13].
Eight patients also had TSC. The 13 classified as probable
LAM had a clinical history compatible with LAM, lung
cysts on CT, but no extra-pulmonary features or evidence
of TSC. 33/58 (57%) presented with pneumothorax, 16/58
(28%) with breathlessness alone, four with chylous collec-
tions and six incidentally after CT scans performed for un-
related problems. A lung biopsy had been performed for
diagnosis in 22/58 patients. One or more angiomyolipo-
mas defined radiologically or after histological analysis
were present in 31/58 patients (53%). Patients were slightly
older than control subjects (median age 46 yrs, interquar-
tile range (IQR) 16.0 vs. 36, IQR 12.3, p= 0.0003) which
was factored into the analysis. Only two controls and one
patient had smoked.
Patients were taking standard therapy for LAM includ-
ing bronchodilators and progesterone. Those taking siroli-
mus, doxycycline or post lung transplantation were
excluded from the study. Only the 45 patients with definite
LAM by ERS criteria were included in the comparison of
biomarkers in LAM and controls: those with probable
LAM were used to determine the utility of VEGF-D for
diagnosis.
Serum VEGF-D is significantly elevated in patients with
LAM and is a better diagnostic marker than MMP-2, -9
and ACE
Spearman correlation performed for age against serum
VEGF-D, MMP-2, MMP-9 and ACE showed there was no
significant correlation between age and biomarkers with
the exception of MMP-2 (p= 0.026). Serum VEGF-D
(p< 0.0001), ACE (p= 0.006) and total MMP-2 (p= 0.003)were higher in LAM when compared with controls (Fig-
ure 1). There was a trend toward higher total MMP-9 in
patients with LAM, although this was not significant
(p= 0.058). ROC analysis showed VEGF-D to be the stron-
gest discriminator between those with LAM and controls
(area under curve (AUC) 0.967± 0.02, 95% CI 0.927-
1.007) when compared with ACE (AUC 0.671± 0.069,
95% CI 0.538-0.805), MMP-2 (AUC 0.714± 0.064, 95% CI
0.590-0.839) and MMP-9 (AUC 0.641± 0.069, 95% CI
0.505-0.777) (Figure 1). The sensitivity and specificity of
VEGF-D were 56% and 100% respectively with a positive
predictive value of 100% and a negative predictive value of
61% using a cut off of 800 pg/ml. In our cohort, a value of
440 pg/ml was the optimal discriminative point, correctly
assigning all but 4 cases and all but 1 control. Of the
patients with definite LAM by current ERS criteria, 42%
had a VEGF-D of less than 800 pg/ml. To examine if
VEGF-D was stable over time, we examined serum VEGF-
D over a one year period. The mean baseline level was
1522 pg/ml (SD 1156). For the three month period where
most data were available, there was a 10% rise in VEGF-D
(n= 19 patients, mean rise 158 pg/ml, SD 254). Over this
period, none with raised VEGF-D fell below 800 pg/ml
but one patient with a borderline level at baseline
increased above the 800 pg/ml diagnostic threshold
(Figure 2).
Utility of the ERS criteria combined with VEGF-D for the
identification of LAM in patients with cystic lung disease
As VEGF-D was the most sensitive and specific diagnostic
marker we examined whether measurement of serum
VEGF-D could reduce the need for lung biopsy in patients
with suspected LAM and how VEGF-D measurement con-
tributed to diagnosis as defined by the recent ERS criteria.
To do this, patients were reclassified into either ‘definite’
or ‘probable’ LAM according to ERS criteria but without
reference to information from lung biopsy. Application of
ERS criteria, without biopsy information, allowed a definite
diagnosis of LAM in 40 of 58 patients (69%) without the
need for biopsy. Interestingly 17 of these 40 had had a lung
biopsy, all of which confirmed LAM. Of the remaining 18
patients where ERS criteria could not make a definite diag-
nosis without lung biopsy, six of these had a VEGF-D level
of >800 pg/ml suggesting a further 10% of patients could
avoid lung biopsy for a definite diagnosis of LAM were this
criteria to be added to diagnostic guidelines (Figure 3).
Association of serum biomarkers with lung function
parameters
We next examined if these biomarkers were related to dis-
ease severity. VEGF-D, ACE and MMP-9 levels were not
associated with percent predicted or absolute FEV1 or
TLCO. Surprisingly, a higher total MMP-2 was associated
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Figure 1 Biomarker levels in patients with LAM and controls. (a) Scatter plots comparing patients with definite LAM and controls for: VEGF-D,
ACE, MMP-2 and MMP-9. All p values were calculated using Mann–Whitney test and corrected for age. Horizontal lines are the group means. (b)
Receiver operating characteristic curves for VEGF-D, ACE, MMP-2 and MMP-9.
















Figure 2 Stability of VEGF-D over time. Serum VEGF-D over time for 19 patients with LAM. Each line represents an individual patient.








































Figure 3 Analysis of diagnostic utility of VEGF-D. (a) Patients are classified based on whether a definite diagnosis of LAM using ERS criteria can be
made without reference to biopsy data. Open circles indicate those patients who underwent lung biopsy all of whom were confirmed to have LAM by
histological analysis. Solid line shows the proposed cut off of 800 pg/ml VEGF-D used to support the diagnosis of LAM. (b) Algorithm using diagnostic
strategy based upon application of ERS criteria with the inclusion of serum VEGF-D measurement prior to lung biopsy. Figure shows the number from
the initial 58 patients in whom a definite diagnosis of LAM can be made at each stage.
Chang et al. Respiratory Research 2012, 13:34 Page 5 of 9
http://respiratory-research.com/content/13/1/34Spearman 2 tailed correlation whether actual or percent
predicted values were considered (Figure 4. ACE and
MMP-9 data not shown). A generalized linear model with
FEV1 percent predicted as the dependent variable and age
and biomarkers as covariates confirmed the association with
MMP-2 (p=0.0023), within the limits of our relatively small
sample size.
To determine if VEGF-D is associated with disease activ-
ity rather than extent of lung function abnormality at a sin-
gle time point we tested if those with higher VEGF-D
experienced a more rapid decline in FEV1. Historical lung
function data of greater than three years duration were
available for 19 patients. The overall rate of decline in FEV1
calculated by linear regression was 113 ml/year (range 28
–461 ml/year). Rate of FEV1 decline in individuals was not
associated with VEGF-D level (p= 0.48, Spearman’s Rho).VEGF-D is a marker for lymphatic involvement but not
angiomyolipomas
As VEGF-D is a lymphangiogenic protein we examined
if patients with lymphatic involvement had higher levels
of VEGF-D than other patients. In the 29 patients for
whom abdominal CT data were available, those with
lymphatic involvement had higher VEGF-D levels thanthose who did not (p = 0.004). VEGF-D was not asso-
ciated with the presence of angiomyolipomas (Figure 5).Quality of life is associated with lung function
Median overall score for the SGRQ was 30.86 (IQR 36.21)
and higher overall score was associated with lower percent
predicted FEV1 (R
2=0.533, p=0.0003) and TLCO (R2=0.499,
p=0.0005) (Figure 6). Similar findings were seen with the
component scores of symptoms, activity and impact (data not
shown).Discussion
In this study we evaluated the diagnostic utility of the
recent ERS LAM guidelines and clinical use of four
serum biomarkers. After prospective application of the
ERS criteria to a national cohort, only 30% of these
patients remained without a definite diagnosis and this
could be reduced to 20% by adding a VEGF-D level of
>800 pg/ml. Our data confirm the finding that VEGF-D
is elevated in LAM [18,26] and in our cohort, has a diag-
nostic specificity of 100% but a sensitivity of only 56%:
suggesting that an elevated VEGF-D is helpful in con-
firming the diagnosis of LAM, but a normal VEGF-D level
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Figure 5 Association of VEGF-D with lymphatic involvement and angiomyolipomas. VEGF-D level is associated with (a) lymphatic
involvement but not (b) the presence of angiomyolipomas. (Mann–Whitney test).


















































































Figure 4 Correlation of biomarkers with lung function. VEGF-D levels are not correlated with (a) percent predicted FEV1 or (b) percent
predicted TLCO. (c) serum MMP-2 levels are associated with percent predicted FEV1 and (d) percent predicted TLCO.
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Figure 6 Correlation of total St. George’s Respiratory
Questionnaire score with percent predicted FEV1 and percent
predicted TLCO.
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which improves confidence in the measurement. Although
not evaluated here, importantly, Young et al. [17] have
demonstrated that VEGF-D can also discriminate between
LAM and the other cystic diseases, pulmonary Langerhans
cell histiocytosis, Birt Hogg Dubé disease and emphysema.
The value that best classified subjects into either the LAM
or healthy control group was 440 pg/ml in this cohort, this
value is lower than that reported by Young et al., probably
due to the use of healthy women as our control popula-
tion. Taken together, our findings suggest that increased
knowledge and application of the ERS diagnostic criteria
amongst respiratory physicians could reduce the use of
lung biopsy in suspected LAM and this could be improved
further by incorporating VEGF-D measurement into the
diagnostic workup. The observation that VEGF-D is asso-
ciated with lymphatic disease rather than lung function de-
cline or other aspects of disease activity or phenotype is
consistent with a recent clinical trial where VEGF-D in
patients with LAM was suppressed by inhibition of the
mTOR pathway but did not parallel changes in lung func-
tion [15].In contrast to Odajima et al. [21] we found that
serum MMP-2 is significantly elevated in LAM. The
finding of raised MMP-2 in LAM patient serum is
consistent with the observation that LAM derived
cells in culture produce excess amounts of MMP-2
which may have therapeutic implications if the pro-
tein is activated locally in LAM lesions [27,28]. It is
unclear why better lung function is associated with a
higher MMP-2 level, although it is unlikely to be an
artefact as this was consistent for both FEV1 and
TLCO. It is possible that MMP-2 production may fall
in advanced disease or conversely, MMP-2 may be a
protective mechanism against lung destruction. Al-
though MMP-2 and −9 were not useful as diagnostic
or prognostic indicators, it remains to be seen
whether MMP inhibition will affect disease progres-
sion in LAM and the role of MMP-2 requires par-
ticular investigation.
The presence of angiotensinogen, angiotensin II,
receptors for angiotensin II and ACE in LAM lung tissue
has been described by Valencia et al. [22] and it has
been postulated that a LAM specific renin-angiotensin
system may play a role in LAM cell proliferation and
migration. Our observation that serum ACE is increased
in LAM would be consistent with several possibilities,
including release of ACE from LAM cells, cleavage of
membrane bound ACE, again, possibly by MMPs [29],
or a result of secondary changes to the cardiovascular
system in response to the burden of cystic lung disease.
The relatively poor separation of ACE levels between
patients and controls make this measurement unhelpful
as a diagnostic tool.
The overall composite score of the SGRQ and the
components relating to symptoms, activity and impact
correlated well with percent predicted FEV1 and
TLCO in keeping with other studies [2,30]. It remains
to be seen whether the SGRQ will add any further in-
formation above lung function measurements but it
deserves evaluation as a marker of treatment response
in clinical trials.
Certain caveats apply to the study. Despite this
being a relatively large and detailed study for a rare
disease, absolute numbers are small for some aspects
of the analysis. Also the lung function decline data is
retrospective and needs to be repeated in a prospect-
ive study. Our patient group encompassed approxi-
mately one third of all patients within the country
and included the full spectrum of patients from those
with no symptoms to those being evaluated for pul-
monary transplantation. The cohort is similar to other
cohorts with respect to age at presentation and rate
of decline in lung function and we feel this makes
our findings applicable to a range of patients being
evaluated for possible LAM.
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Of the biomarkers examined, serum VEGF-D alone had
a sufficient positive predictive value for use as a diagnos-
tic test for LAM. When used in combination with the
ERS diagnostic criteria 80% of patients could avoid lung
biopsy for diagnosis. Total MMP-2 was elevated in LAM
patients although the significance of these observations
needs further investigation at a mechanistic level. With the
exception of total MMP-2, no serum biomarker was asso-
ciated with lung function or disease activity. The SGRQ
correlates well with FEV1 and TLCO in patients with
LAM and may be a useful assessment tool, particularly in
those who find pulmonary function tests difficult. Its role
as an endpoint in an interventional study should be
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